What Lunatus does

Lunatus Marketing & Consulting FZCO is a Dubai-headquartered, private healthcare commercialization partner founded in 2003 by Lina Kouatly (President & CEO). The company acts as the regional conduit between international pharmaceutical and healthcare manufacturers and the markets of the Arabian Gulf and Middle East, operating across nine countries: UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq. It commercializes 300+ product lines sourced from 40+ global healthcare partners across 16 therapeutic categories including cardiovascular, dermatology, ENT, gastroenterology, gynecology, infectious diseases, internal medicine, neurology, oncology, ophthalmology, orthopaedic, pain management, pediatrics, psychiatric, vascular, and weight loss.

The company's offering is structured as a full-stack commercialization service — covering in-house regulatory affairs supported by in-house legal counsel, sales force deployment, marketing execution, distribution logistics, and supply chain management — that replaces the need for international pharma companies to engage multiple local vendors when entering the region. Underlying technology is not specified, and there is no disclosed proprietary software platform or AI component; the value lies in process integration, regulatory know-how, and regional infrastructure rather than technology IP. The company is privately held with no disclosed parent, funding rounds, or institutional shareholders.

Revenue is generated through exclusive distribution and commercialization agreements: Lunatus retains exclusive commercialization rights for partnered products in defined Middle Eastern territories and shares economics with the originator via upfront payments, regulatory and commercial milestone payments, and a significant share of in-region product revenue. Recent marquee agreements include an exclusive partnership with LENZ Therapeutics for VIZZ (aceclidine ophthalmic solution) for presbyopia, signed in January 2026. Pricing is not publicly disclosed, revenue figures are not publicly disclosed, and the firm employs between 51 and 100 people across its regional operations.

Name

Lunatus

Legal name

Lunatus Marketing & Consulting FZCO

Website

https://lunatus-me.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Lunatus is a Dubai-based, private healthcare commercialization partner founded in 2003 that gives international pharmaceutical companies exclusive regulatory, sales, marketing, distribution, and supply chain access across nine Middle Eastern countries, commercializing 300+ products from 40+ global partners.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution and Commercialization Services

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Wholesale Trade Agents and Brokers (425120)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

akta.pro secondary industry

International / Market Entry & Expansion Marketing Strategy (MPAAAFAL)

Keywords

• Pharmaceutical distribution
• Healthcare commercialization
• Regulatory affairs services
• Pharmaceutical marketing
• Medical supply chain

Headquarters

HQ city

Dubai

HQ country

United Arab Emirates

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Distribution and Commercialization Rights: Lunatus generates revenue through exclusive distribution agreements with global healthcare companies. They receive upfront payments, regulatory milestones, commercial milestones, and a significant share of product revenue from sales in the Middle East region.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Lunatus acts as a full-service healthcare commercialization partner for global pharmaceutical and healthcare companies seeking to enter Middle East markets. The company delivers integrated regulatory, sales, marketing, distribution, and supply chain solutions, and commercializes a portfolio of 300+ product lines across 16 therapeutic categories sourced from 40+ international partners. Its core revenue model combines exclusive distribution rights with milestone payments and revenue shares from partnered product launches in the Arabian Gulf region.

Product overview

Lunatus operates as a full-service healthcare commercialization partner rather than a product manufacturer. The company offers regulatory, sales, marketing, distribution, and supply chain solutions to help global pharmaceutical companies enter and expand in Middle East markets. Their portfolio spans 16 therapeutic categories (Cardiovascular, Dermatology, ENT, Gastroenterology, Gynecology, Infectious Diseases, Internal Medicine, Neurology, Oncology, Ophthalmology, Orthopaedic, Pain Management, Pediatrics, Psychiatric, Vascular, and Weight Loss) across 300+ product lines from 40+ international partners. A notable product within their Ophthalmology category is VIZZ (aceclidine ophthalmic solution), which they commercialize in the Middle East in partnership with LENZ Therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

• Healthcare Product Portfolio (300+ product lines across 16 therapeutic categories) Diverse portfolio of over 300 healthcare product lines across 16 therapeutic categories (Cardiovascular, Dermatology, ENT, Gastroenterology, Gynecology, Infectious Diseases, Internal Medicine, Neurology, Oncology, Ophthalmology, Orthopaedic, Pain Management, Pediatrics, Psychiatric, Vascular, and Weight Loss), sourced from more than 40 global pharmaceutical partners and commercialized for global healthcare companies seeking to reach Middle East markets.
• VIZZ (aceclidine ophthalmic solution) Aceclidine ophthalmic solution for the treatment of presbyopia, commercialized in the Middle East under an exclusive partnership with LENZ Therapeutics. Lunatus holds exclusive commercialization rights across nine Middle Eastern countries.
• Regulatory Affairs Services Regulatory support delivered through an in-house regulatory team that works hand-in-hand with the company's legal counsel to navigate complex Middle East approval requirements for partnered pharmaceutical and healthcare products.
• Sales Services Sales force deployment and execution for partnered pharmaceutical and healthcare products across the Arabian Gulf and Middle East region.
• Marketing Services Comprehensive marketing strategy crafting and execution for partnered healthcare brands across the Middle East region.
• Distribution Services Distribution strategy and execution that delivers partnered pharmaceutical and healthcare products across nine Middle Eastern countries (UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq).
• Supply Chain Management Services Reliability-focused supply chain management woven into every stage of the product lifecycle, ensuring product security for partnered pharmaceutical and healthcare brands across the Middle East.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• LENZ TherapeuticscoreChannel Partner/ Reseller/ Distributor · 5 January 2026Exclusive commercialization partnership for VIZZ (aceclidine ophthalmic solution) for treating presbyopia in the Middle East region, covering UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq. LENZ receives upfront, regulatory and commercial milestone payments plus a significant share of revenue, while Lunatus retains exclusive commercialization rights. This is LENZ's fourth international commercialization partnership for VIZZ, which received FDA approval in July 2025 and launched in the US in September 2025.
• 40+ Global Healthcare CompaniescoreChannel Partner/ Reseller/ DistributorPartnered with over 40 global companies offering 300 diverse product lines to meet the growing healthcare needs of the Middle East region across cardiovascular, dermatology, ENT, gastroenterology, gynecology, infectious diseases, internal medicine, neurology, oncology, ophthalmology, orthopaedic, pain management, pediatrics, psychiatric, vascular, and weight loss categories.

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Algorithm SAL: Lebanon-based pharmaceutical company with manufacturing and regional distribution across MENA, including in-licensed and proprietary branded generics. Comparable regional pharmaceutical distributor serving overlapping Middle Eastern markets.
• Tabuk Pharmaceuticals: Saudi-based pharmaceutical company with manufacturing, in-licensing, and regional distribution across multiple therapeutic categories. Directly comparable to Lunatus's business model of partnering with global innovators for Middle East commercialization.
• Neopharma: Abu Dhabi-headquartered pharmaceutical manufacturer with regional distribution across the GCC. Operates a similar in-licensing and distribution model serving MENA markets and overlapping with Lunatus's therapeutic categories.
• Julphar (Gulf Pharmaceutical Industries): Ras Al Khaimah-based pharmaceutical manufacturer and distributor with broad MENA presence across multiple therapeutic categories. Direct comparable: UAE-headquartered pharma player offering branded generics and licensing partnerships across the same Gulf geographies Lunatus serves.
• Pharmax Pharmaceuticals: UAE-based pharmaceutical company specializing in branded generics and in-licensed products with regional distribution across the Middle East. Closely comparable business model — in-licensing, marketing, and distribution via regional channel partners.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances): Saudi-listed pharmaceutical manufacturer and distributor serving KSA and export markets with branded and licensed products. Comparable regional distribution footprint and licensing/partnership-driven model targeting the same Middle Eastern customer base as Lunatus.
• Jamjoom Pharmaceuticals: Saudi-based pharmaceutical company with manufacturing, marketing, and distribution of branded generics and licensed products across MENA. Comparable in-licensing/distribution orientation and GCC market focus.

Broad incumbents

• Cipla: India-headquartered global pharmaceutical major with active presence in the Middle East via distribution partnerships and direct operations. Comparable as both a potential partner to Lunatus and a broader incumbent operating in the same regional channel.
• Hikma Pharmaceuticals: Jordan-headquartered multinational pharmaceutical company with deep MENA commercial infrastructure, branded and generics portfolio, and a licensing/distribution model overlapping Lunatus's go-to-market. Larger and more diversified, but operates in the same channel.

Regional players

• Acino International: Switzerland-headquartered but with a strong Middle East/Turkey focus for specialty pharmaceuticals via partnerships and out-licensing. Comparable as a partner-to-Lunatus originator (or regional distributor) rather than a direct competitor in the Gulf.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/LunatusME
• LinkedInlinkedin.com/company/lunatus-global

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lunatus